Madeline Halpert
and
Nadine Yousif
U.S. President Donald Trump announced that health professionals should reconsider prescribing Tylenol, known scientifically as acetaminophen, for pregnant women. This advice follows controversial claims linking the pain reliever to autism.
During a statement, Trump stated that Tylenol is “no good” for expectant mothers and recommended its use only in severe cases of fever. The remarks have prompted significant backlash from medical experts who categorize them as potentially harmful.
Officials from the UK have affirmed that paracetamol remains the safest pain management option during pregnancy.
Dr. Steven Fleischman, president of the American College of Obstetricians and Gynecologists, criticized Trump’s announcement as lacking support from substantial scientific research, emphasizing that the causes of neurological issues in children are multifaceted.
The college has consistently supported the use of Tylenol as one of the only deemed safe painkillers for pregnant women, stating that existing studies do not provide evidence of a direct link between acetaminophen use during any trimester and developmental issues in fetuses.
Furthermore, Tylenol is recommended by various leading medical organizations globally.
Kenvue, the manufacturer of Tylenol, stated that research indicates acetaminophen does not trigger autism. They expressed concern regarding Trump’s comments and their potential implications for maternal health.
The FDA, under Health Secretary Robert F. Kennedy Jr., plans to issue a warning to physicians about the supposed risks associated with Tylenol during pregnancy and will initiate changes to safety labeling on the product.
The agency is also exploring the approval of leucovorin, traditionally a treatment for chemotherapy side effects, for autistic children, based on preliminary studies suggesting it may enhance communication skills in those with folate deficiencies.
However, researchers caution that the understanding of potential treatments for autism remains in its infancy, requiring further investigation.
The Autism Science Foundation highlights that while low folate levels in early pregnancy have been connected to some autism cases, the research is inconsistent across numerous studies.
Research indicates that mothers supplementing with folic acid near conception may reduce the likelihood of autism in their offspring. Yet, contradictory findings persist in other studies.
Some preliminary studies utilizing leucovorin have suggested potential benefits, as this form of folic acid may effectively cross the blood-brain barrier.
The complexity of identifying autism’s causes is highlighted, with experts emphasizing that it results from an intricate interplay of genetic and environmental elements, as evidenced by rising autism diagnoses.
Getty Images
A recent review conducted by the dean of Harvard’s Chan School of Public Health suggested a potential correlation between Tylenol use during pregnancy and neurodevelopmental disorders. Nevertheless, experts reiterated the necessity of treating maternal pain and fever, which can also pose risks to fetal health.
An extensive study involving 2.4 million children in Sweden has failed to establish a causal link between Tylenol and autism. This study, which examined children born between 1995 and 2019, found that the incidence of autism was not significantly different between children who were exposed to acetaminophen in utero and those who were not.
In summary, while the discussion around Tylenol’s safety in pregnancy continues to evolve, current medical consensus suggests that it remains a suitable option, emphasizing the importance of clear evidence and sound guidance for expectant mothers.
